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Simple Summary: Pancreatic cancer is a highly fatal disease that does not respond well to current
cancer therapies. We previously showed that protein kinase C iota (PKCι) is highly expressed in
pancreatic cancer, and inhibition of PKCι signaling in human pancreatic cell lines blocks tumor
growth. In this study, we used a genetic mouse model to investigate the role of PKCι in pancreatic
cellular homeostasis and pancreatic tumorigenesis. We found that inhibition of PKCι expression in
the mouse pancreas blocked autophagy, altered infiltration of immune cells, and prevented pancreatic
cancer formation. Taken together, these findings reveal a promotive role for PKCι in pancreatic
cancer development.
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Abstract: Protein kinase C iota (PKCι) functions as a bonafide human oncogene in lung and ovarian
cancer and is required for KrasG12D -mediated lung cancer initiation and progression. PKCι expression is required for pancreatic cancer cell growth and maintenance of the transformed phenotype;
however, nothing is known about the role of PKCι in pancreas development or pancreatic tumorigenesis. In this study, we investigated the effect of pancreas-specific ablation of PKCι expression
on pancreatic cellular homeostasis, susceptibility to pancreatitis, and KrasG12D -mediated pancreatic
cancer development. Knockout of pancreatic Prkci significantly increased pancreatic immune cell
infiltration, acinar cell DNA damage, and apoptosis, but reduced sensitivity to caerulein-induced
pancreatitis. Prkci-ablated pancreatic acinar cells exhibited P62 aggregation and a loss of autophagic
vesicles. Loss of pancreatic Prkci promoted KrasG12D -mediated pancreatic intraepithelial neoplasia
formation but blocked progression to adenocarcinoma, consistent with disruption of autophagy. Our
results reveal a novel promotive role for PKCι in pancreatic epithelial cell autophagy and pancreatic
cancer progression.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer.
With a 5-year survival rate of 10%, PDAC is predicted to result in over 48,000 deaths in the
U.S. in 2021 [1]. This high mortality rate is attributable to late detection and poor response
of PDAC to conventional therapies. Current treatment options elicit a limited therapeutic
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response, in most cases only prolonging patient survival by a matter of weeks to months [2].
The lack of durable therapeutic responses highlights the critical need to identify more
effective therapeutic targets for the treatment of pancreatic cancer.
PDAC development is thought to progress from low grade dysplasia, pancreatic intraepithelial neoplasia 1-2 (PanIN1-2), to high grade dysplasia (PanIN3), before advancing
to adenocarcinoma [3]. Greater than 90% of all PDACs contain an activating KRAS mutation,
and expression of an oncogenic mutant of Kras (KrasG12D ) in mouse pancreatic epithelium
(Lox-Stop-Lox-KrasG12D ; Ptf1aCre/+ ; KC genetically engineered mouse model; GEMM) recapitulates the full spectrum of human PDAC development [4–9]. KrasG12D -induced PanINs
are detectable in the pancreas by 1-2 months of age as small focal lesions. PanIN lesion
initiation and progression continue over the lifespan of the mouse with a small subset of
the high grade PanINs progressing to pancreatic cancer [8]. The overall similarity of this
model to human disease development makes the KC mouse a useful GEMM to assess the
role of specific genes in pancreatic tumorigenesis and to evaluate potential therapeutic
targets for the prevention and treatment of PDAC [9–11].
Atypical protein kinase C (PKC) iota, PRKCI, is highly expressed in numerous cancers [12] and is a bonafide human oncogene in lung and ovarian cancers [13,14]. Specifically,
the protein product of PRKCI, PKCι, is overexpressed in a large percent of lung and ovarian cancers where high PKCι expression predicts poor survival, and disruption of PKCι
signaling blocks cancer cell transformed growth and tumor formation [13,15–18]. We and
others have shown that PRKCI is consistently elevated in PDAC compared to paired normal
tissue [19,20], and that inhibition of PKCι expression in pancreatic cancer cell lines significantly reduces pancreatic cancer cell growth in vitro, and tumor growth, angiogenesis, and
metastasis in vivo demonstrating that PKCι is required for the transformed phenotype of
PDAC cells [20].
Prkci plays a promotive role in KrasG12D -mediated initiation of lung and colon carcinogenesis [12,16,21]. In the KrasG12D -driven, KC model of pancreatic tumorigenesis, PKCι
expression is elevated in both early PanIN lesions and adenocarcinoma, similar to human
disease [22]. In the current study, we used tissue-specific ablation of Prkci, the gene expressing murine PKCι, to investigate the role of PKCι in pancreas homeostasis, susceptibility to
pancreatitis, and in the initiation and progression of pancreatic cancer. We report that mice
lacking pancreatic PKCι expression developed normally but exhibited increased pancreatic
apoptosis and immune cell infiltration and a lack of autophagy in pancreatic acinar cells.
Consistent with the required role for autophagy in pancreatic cancer development, ablation
of pancreatic PKCι blocked progression of early KrasG12D -mediated PanINs.
2. Materials and Methods
2.1. Mice
Floxed PKCiota (Prkcif/f ) mice (previously described [23–25]) are maintained in the
Mayo Clinic Florida barrier facility. Ptf1aCre/+ mice were a gift from Pinku Mukherjee,
University of North Carolina [26]. Prkcif/f mice were crossed with Ptf1aCre/+ mice to generate Ptf1aCre/+ ; Prkcif/+ mice. These mice were then crossed to generate Ptf1aCre/+ , Prkcif/f
(Prkci∆panc ), and Prkcif/f mice.
LSL-KrasG12D mice were originally obtained from the NCI Mouse Repository. LSLG12D
Kras
mice were crossed with Ptf1aCre/+ mice to generate LSL-KrasG12D ; Ptf1aCre/+ mice
(KC mice), as described [8,27]. LSL-KrasG12D ; Prkcif/f mice [13] were crossed with KC mice
to generate LSL-KrasG12D ; Ptf1aCre/+ , Prkcif/f (KCI) mice. Recombination of the floxed alleles
was confirmed by PCR analysis of genomic DNA as described [24]. Mice were housed in
microisolator cages in a pathogen-free barrier facility and maintained at a constant temperature and humidity on a 12h light/12h dark cycle. Mice were provided a standard irradiated
rodent chow (PicoLab Mouse Diet 20 5058; LabDiet, St. Louis, MO, USA) and filtered
water ad libitum throughout the experimental protocol unless otherwise specified. All mice
were visually checked daily for body condition, and mice on the experimental protocol
were weighed twice weekly. All mice were euthanized by CO2 inhalation according to

Cancers 2022, 14, 796

3 of 23

the American Veterinary Medical Association Guidelines. All animal experiments and
procedures performed were approved by the Mayo Clinic Institutional Animal Care and
Use Committee (IACUC protocols A48510; A72513, A00002363).
To analyze tissue proliferation, one hour prior to harvest, mice were injected intraperitoneally with 50 ug/kg 5-bromo-20 -deoxyuridine (BrdUrd; Sigma-Aldrich, St. Louis, MO).
At harvest, mice were weighed and the pancreata were removed, blotted dry on filter paper
and weighed, and fixed in 10% formalin for H&E and immunohistochemical (IHC) analysis.
Differences in survival between genotypes, and between sexes within a genotype, were
analyzed by Kaplan-Meier survival analyses performed using Graphpad Prism. Survival
was defined as the age when a mouse died, was moribund, and/or met IACUC-defined
humane endpoints for euthanasia, such as weight loss, decreased activity, body condition
score, or behavioral changes.
2.2. Mouse Models of Caerulein-Induced Pancreatitis
To induce acute pancreatitis, 1–2 month old mice were injected intraperitoneally with
50 µg/kg caerulein (American Peptide, Sunnyvale, CA, USA) hourly for 8 hr and harvested
1 hr after the last caerulein injection [28]. To induce severe acute pancreatitis, 1–2 month
old mice were injected intraperitoneally with 250 µg/kg caerulein twice daily for two
weeks and harvested 24 h after the last caerulein injection [29]. Note that although this
dosing regimen has been previously referred to as “chronic pancreatitis” [29], in true
clinical chronic pancreatitis, the tissue does not heal, with regions of acinar tissue replaced
with persistent acinar-to-ductal metaplasia (ADM), fibrosis, and inflammation. In this
two-week cerulein-induced model of pancreatitis, the tissue is restored to histologically
normal tissue within a week after ceasing the caerulein treatments. We therefore now refer
to this treatment as “severe acute pancreatitis”. Mice were weighed immediately before
euthanasia and blood was drawn immediately after euthanasia. For serum collection,
blood was drawn from the posterior vena cava immediately after euthanasia, coagulated
at room temperature for 30 min and serum was collected by centrifuging for 10 min at
10,000× g. Serum amylase was measured using the Phadebas amylase test (Magle Life
Sciences, Cambridge, MA, USA) according to the manufacturer’s instructions. After serum
removal, the pancreata was removed, blotted on a paper towel, weighed, and immediately
fixed in 10% formalin for H&E, Masson’s trichrome staining, and IHC analysis.
2.3. Immunoblot, Histological, and IHC Analyses
PKCι expression was detected by immunoblot analysis of protein extracted from the
whole pancreas of 1.5 month old mice [30]. Pancreas tissues were processed for histology,
aligned, and embedded for sectioning, and approximately 100 µm of tissue was removed
to reach a full cross-section of the pancreas. Sections measuring 5 µm were then cut and
stained by IHC as described previously [31]. One slide of pancreas tissue/mouse (typically
5–6 mice/group; see Figure legends for group sizes) was subjected to IHC detection of each
antigen of interest. Group size was dependent on the number of available pancreas tissues
at the time the analysis was performed. Stained slides were scanned at 20× magnification
using Aperio ScanScope (Leica Biosystems, Buffalo Grove, IL, USA) to produce digital
images. Aperio Imagescope software was used to annotate the digital image of the pancreas
for quantitative analysis, excluding artifacts and non-pancreatic tissue. In some cases, an
individual slide was stained either too dark or too light for automated analysis to be
performed accurately, and therefore, that slide was not included in the analysis. The
annotated area of the pancreas, typically a minimum area of 7–10 mm2 /slide, or in the case
of nuclear staining, a minimum of ~30,000 cells/slide, was analyzed. For the quantitation of
antigen detection in PanIN lesions, only the PanIN-containing area of tissue was annotated
for analysis. Quantitative analysis was performed using the Spectrum software IHC
Nuclear V1 algorithm or IHC Positive Pixel count V9 algorithm, and data are presented
as the percent positive stained nuclei, or percent positive staining area, respectively. All
available data are presented, and no data points were eliminated as outliers.
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H&E stained slides were used to evaluate edema and acinar cell damage (calculated
as % non-normal or ADM histology) for pancreatitis damage score calculation [32]. H&E
stained pancreas from 18 month old KC and KCI was evaluated by a clinical pathologist
(M.K.) to determine the highest grade of tumor present using well-described criteria [8].
Antibody information is provided in Table S1.
2.4. Reactive Oxygen Species Assay
Pancreata were harvested from 1.5 month old mice and quick-frozen in an Optimal
Cutting Temperature compound (Sakura). Sections measuring 6 µm were incubated with
30 uM dihydroethidium (DHE; Molecular probes) for 8 min. Sections were then mounted
with Vectrashield hard mounting media containing DAPI and imaged immediately by
fluorescence microscopy.
2.5. Transmission Electron Microscopy
Six week old mice were fasted overnight, anesthetized with 100 mg/kg ketamine/
10 mg/kg xylazine, and perfused with fixative (2% paraformaldehyde with 2.5% glutaraldehyde in phosphate-buffered saline, pH 7.2) via the vena cava. Death was confirmed by
opening the chest cavity. The pancreata were removed and immersed in fixative at 4 ◦ C
until processed (at least 12 h). The tissue was rinsed with 0.1 M phosphate buffer and secondarily fixed in 1% osmium tetroxide followed by 2% aqueous uranyl acetate. Tissue was
dehydrated in sequential ethanol washes followed by 100% acetone and embedded in Embed
812/Araldite epoxy resin and polymerized for 24 h at 60 ◦ C. Ultrathin sections (0.1 micron)
were post-stained with 2% lead citrate. Micrographs were obtained using a JEOL 1400 Plus
transmission electron microscope (Tokyo, Japan) at 80 kV equipped with a Gatan Orius 4K
camera (Pleasanton, CA, USA).
2.6. Rapamycin Treatment
Five to six week old mice were injected intraperitoneally with 0.2 mg/kg rapamycin
or diluent (0.08% ethanol) 6 days/week for 2 weeks. Mice were harvested and the pancreas
fixed in 10% buffered formalin and processed for IHC analysis.
2.7. Analysis of TCGA-PDAC Gene Expression and Patient Survival Data
Computational Analysis: RNA-seq data, gene-level copy number alterations estimated
by the Genomic Identification of Significant Targets In Cancer (GISTIC), and survival data
for the primary pancreatic ductal adenocarcinoma tumors in the Pancreatic Adenocarcinoma (PanCancer Atlas; PDAC) dataset were downloaded from the Cancer Genome
Atlas (TCGA) data portal (http://www.cbioportal.org/public-portal/; RNA-seq data last
accessed 30 January 2020 and survival data last accessed 11 November 2019) [33,34].
Gene Signature Score Analysis of PDAC: The gene signature score represents the
principal component analysis (PCA) of the expression matrix of the PKCι-ECT2 signature.
The gene/pathway signature score was applied using the built-in R prcomp and princomp
functions. The PKCι-ECT2 pathway signature consists of the 10 ribosomal RNA processing
genes that most highly correlate with PRKCI and ECT2 expression in the TCGA PDAC
dataset. The Spearman correlation coefficient and p-value are listed in Figure S9B. The
autophagy risk score consists of the 10 autophagy-related genes with a prognostic value
in PDAC and was constructed as a risk model based on the expression of these genes [35].
The risk score was calculated using the following formula: risk score = (0.1063 × CASP4) +
(0.0416 × CHMP2B) + (0.0297 × EIF4G1) − (0.0498 × GABARAP) + (0.0983 × NCKAP1)
− (0.2125 × PELP1) − (0.1453 × RAB24) − (0.3239 × RPTOR) + (0.0078 × TNFSF10) −
(0.1622 × WIPI2).
Ingenuity Pathway Analysis (IPA): To identify genomic signatures associated with
PRKCI expression in human PDAC tumors, we performed IPA on the TCGA PDAC dataset
consisting of 146 primary PDAC tumors. Genomic data from tumors corresponding to
the 25% of PDAC tumors with the highest PRKCI mRNA levels (Top25; n = 36) and those

Cancers 2022, 14, 796

5 of 23

corresponding to the 25% of tumors with the lowest PRKCI expression (Btm25; n = 36)
were compared. Genes that were differentially expressed with significance (p-value < 0.05;
fold change > 1.5) between these groups were subjected to IPA. The core IPA analysis
was performed using default settings: direct and indirect relationships between molecules
supported by experimentally observed data were considered, networks did not exceed
35 molecules, and all sources of data from human studies in the Ingenuity Knowledge Base
were considered. This generated priority lists for canonical pathways. Score values were
calculated from hypergeometric distribution and right-tailed Fisher’s exact test. Canonical
pathways were further filtered by −log(p-value) > 1.3 and Z-score > 1.3 or <−1.3.
Survival Analysis: PDAC patients surviving >30 days were stratified by PRKCI expression and segregated into high PRKCI and low PRKCI expression groups optimized for
survival outcome based on an optimized cutoff value of PRKCI expression calculated using
the R survival package [36]. The optimal cutoff was defined as the point with the most
significant statistical difference in overall survival (log-rank test) using the R functions
survfit and coxph. To assess whether the presence of PRKCI copy number gains (CNGs)
was prognostic for PDAC patient survival, PDAC patients with PRKCI CNGs, and without
PRKCI CNGs, were compared for overall survival.
2.8. Statistical Analysis
Individual unpaired t-tests, without correction for multiple comparisons, with alpha = 5%
were used to compare positive immunostaining between Prkcif/f and Prkci∆panc groups and
KC and KCI groups, and to compare the zymogen granules per cell between groups. Twoway analysis of variance with Bonferroni’s multiple comparisons test was used to compare
pancreas/body weight and serum amylase of WT and Prkci∆panc mice treated with saline or
caerulein, and the percent of abnormal pancreas in KC and KCI mice. Fisher’s exact test was
used to compare the presence of damage following induction of severe acute pancreatitis in
WT and Prkci ∆panc mice and PanIN progression in KC versus KCI mice. A chi-square test was
used to assess the significance of the distribution of PDAC-TCGA tumors with and without
CNGs into high PRKCI and low PRKCI groups. The log-rank (Mantel-Cox) test was used to
compare survival curves. Unless otherwise stated, statistical analyses were performed using
Graphpad Prism. Unless otherwise stated, p ≤ 0.05 was considered statistically significant.
3. Results
3.1. Pancreas-Specific Ablation of Prkci Increased Apoptosis, Cellular Stress, and Immune
Cell Infiltration
Floxed Prkci (Prkcif/f ) mice [25] were crossed with mice expressing Cre recombinase
driven by the Ptf1a promoter (Ptf1aCre/+ mice) [26] to generate mice with pancreas-specific
ablation of Prkci (Prkci∆panc mice). Prkci∆panc mice, and mice with unrecombined floxed
Prkci alleles (Prkcif/f mice), were born at the predicted Mendelian frequency and exhibited
no significant difference in overall survival compared to control mice (Prkci+/+ , Figure 1A;
see also Figure S1). Immunoblot analysis confirmed loss of PKCι protein expression in the
Prkci∆panc pancreas (Figure 1B, see also Figure S2). While ablation of pancreatic Prkci did not
alter the overall morphology of the pancreas tissue (Figure 1C), Prkci∆panc mice exhibited a
significantly lower pancreas weight, as determined by a smaller ratio of pancreas weight
to body weight, that persisted over time (Figure 1D). This result was not attributable to
a significant alteration in body weight (Figure S3) or acinar cell proliferation (Figure 1E).
Instead, the difference in pancreas weight was likely driven by the significantly higher
level of apoptosis detected in Prkci∆panc pancreatic acinar cells, compared to Prkci+/+ and
Prkcif/f pancreatic acinar cells (Figure 1F). Consistent with the pancreatic histology shown in
Figure 1C, the distribution of amylase expressing- (acinar), cytokeratin 19-expressing (ductal), and insulin-expressing (endocrine) cells was similar in Prkcif/f and Prkci∆panc pancreas,
although insulin-staining cells were detected at a slightly, but significantly higher level in
Prkci∆panc pancreas (Figure 2A). Importantly, despite a higher level of acinar cell apoptosis,
Prkci∆panc mice did not exhibit a significantly lower percent of amylase-expressing acinar

Cancers 2022, 14, 796

6 of 23

cells (Figure 2A) or a significantly higher level of serum amylase, an indicator of acinar cell
damage (Figure 2B).

Figure 1. Characterization of pancreas-specific Prkci knockout mice. (A) Kaplan-Meier analysis of the
overall survival of the control (Prkci+/+ ), Prkcf/f , and Prkci∆panc mice is plotted. n = 81, 97, and 112,
respectively. (B) Immunoblot analysis of PKCι protein expression in mouse pancreas (3 representative
mice/genotype). Full immunoblots are in Figure S2. (C) Representative H&E stained pancreas from
each genotype (3.5 month old). Scale bar = 50 µm. (D) The ratio of pancreas weight/body weight at
harvest at indicated ages is plotted. Representative images of IHC detection and quantitative analysis
of IHC staining of (E) cellular proliferation (BrdUrd incorporation) and (F) apoptosis (cleaved caspase3) in mouse pancreas. Analyses were performed on mice harvested at 1.5 months of age, except
as otherwise described. Scale bars = 50 µm. Quantification of pancreas weight/body weight ratio,
cleaved caspase-3 expression, and BrdUrd incorporation is plotted as mean ± SE; n ≥ 6 mice/group.
* p < 0.05 compared to Prkci+/+ and Prkcif/f .
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Figure 2. Ablation of pancreatic Prkci expression increases pancreas immune cell infiltration.
(A) Representative image of IHC detection of acinar (amylase; pink) and ductal (cytokeratin-19,
CK-19; brown) cell markers in the pancreata of 1.5 month old mice (scale bar = 100 µm; left panel).
Quantitation of area of IHC detection of amylase, CK19, and insulin is plotted as mean ± SE; n ≥ 6
(right panel). (B) Basal serum amylase level in 3.5 month old mice (n = 6, 5, respectively) is plotted as mean ± SE. (C) Representative images of IHC detection of infiltrating leukocytes (CD45+ ),
macrophages (F4/80+ ), T-cells (CD3+ ), and neutrophils (Ly6.B+ ) in pancreata of 1.5 month old mice
(scale bar = 50 µm). Quantitative analysis of IHC staining is plotted below images as mean ± SE;
n ≥ 6. * p < 0.05 compared to Prkcif/f .

3.2. Prkci Loss Protected against Caerulein-Induced Pancreatic Damage
We next assessed whether the elevated level of pancreatic acinar cell apoptosis in
Prkci∆panc mice was associated with altered pancreatic immune cell infiltration. Immunohis-
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tochemical (IHC) detection of CD45+ cells revealed a significantly higher level of immune
cells in Prkci∆panc pancreas compared to Prkcif/f pancreas (Figure 2C). Characterization of
the immune cell subtypes present in the Prkci∆panc mouse pancreas revealed a significantly
higher level of macrophages (F4/80+ ) and T cells (CD3+ ), but no difference in neutrophil
infiltration (Ly6B.2+ ; Figure 2C).
Elevated pancreatic immune cell infiltration is also observed in severe acute pancreatitis [37,38]. PKCι expression was higher in clinical pancreatitis than in normal pancreas (Figure 3A), suggesting a potential role for PKCι in the response of acinar cells to
pancreatitis-inducing stimuli. Therefore, we examined the effect of loss of pancreatic PKCι
expression on susceptibility to pancreatitis. Caerulein, a cholecystokinin ortholog, promotes
intracellular activation of digestive enzymes normally secreted by acinar cells, resulting in
acinar cell damage and an inflammatory response that resembles acute or severe acute pancreatitis, depending on the dose and timing of caerulein administration [28,39]. Consistent
with the human disease, PKCι expression was also higher in pancreata exhibiting caeruleininduced severe acute pancreatitis than in pancreata of control-treated mice (Figure 3A,
see also Figure S4). One day of repeated caerulein injections induced acinar cell damage
and pancreatic edema in Prkci+/+ mice, detected as a significantly higher level of serum
amylase (Figure 3B) and pancreas weight (Figure 3C), respectively, similar to the pathology
of acute pancreatitis in humans [28,40]. In the absence of caerulein-treatment, loss of PKCι
expression did not result in histological alterations consistent with pancreatitis (Figure 3D),
even in 18 month old mice (Figure S5). Prkci∆panc mice were partially, but significantly,
protected from an acute pancreatitis-induced increase in serum amylase (Figure 3B), and
this treatment did not induce an increase in pancreas/body weight ratio in Prkci∆panc mice
(Figure 3C), suggesting that loss of pancreatic PKCι expression reduced susceptibility to
caerulein-induced acinar cell damage.
We next investigated the effect of ablation of pancreatic Prkci on the development of
severe acute pancreatitis. Prkci+/+ mice injected with caerulein twice daily for two weeks
exhibited signs of severe acute pancreatitis, including fibrosis, edema, dilated acinar lumina,
and ADM [29], while Prkci∆panc mice exhibited less pancreatic damage (Figure 3D). Furthermore, this two-week caerulein treatment induced a significant influx of macrophages into
Prkci+/+ mouse pancreas (Figure 3E), which is characteristic of severe acute pancreatitis [37].
In contrast, the same two-week caerulein treatment did not induce a significant increase
in the level of macrophages in Prkci∆panc mouse pancreata, compared to control-treated
Prkci∆panc mouse pancreata (Figure 3E). Severe acute pancreatitis significantly increased
both apoptosis and proliferation in Prkci+/+ mouse pancreata (Figure 3F,G). In contrast,
severe acute pancreatitis induced a significant increase in apoptosis in the pancreata of
caerulein-treated Prkci∆panc mice, but proliferation was not significantly increased, suggesting less overall injury (Figure 3F,G). Finally, calculation of an overall pancreatitis damage
score, using a previously described formula incorporating edema, immune infiltration,
and acinar cell damage [32], confirmed significantly less pancreatic damage in Prkci∆panc
mice compared to Prkci+/+ mice (Figure 3H). These results reveal that, despite a baseline
of higher immune cell infiltration and apoptosis, Prkci∆panc mice were protected against
caerulein-induced pancreatitis.
3.3. Loss of Pancreatic Prkci Expression Promoted Pancreatic Oxidative Stress and DNA Damage
and Blocked Acinar Cell Autophagy
To better understand the cellular effects of pancreatic Prkci ablation, we assessed the
level of basal cellular stress in the pancreas of Prkci∆panc and Prkcif/f mice. Reactive oxygen
species were higher in the pancreas of Prkci∆panc mice compared to Prkcif/f mice (Figure 4A).
Prkci∆panc mice also had significantly higher levels of phosphorylated H2A.x (p-H2A.x; a
sensitive marker of DNA damage) [41], p-Chk1 (an indicator of activation of DNA damage
response), and nuclear p53 (an indicator of the cellular stress response) staining in acinar
cells (Figure 4B), suggesting that loss of pancreatic Prkci expression leads to acinar cell DNA
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damage and subsequent p53 activation, likely driving the elevated apoptosis observed in
Prkci∆panc acinar cells (Figure 1E).

Figure 3. Ablation of pancreatic Prkci expression protects against caerulein-mediated damage.
(A) Representative images of IHC detection of PKCι expression in normal human and mouse pancreas, human pancreatitis, and caerulein-induced severe acute mouse pancreatitis (scale bar = 50 µm).
See additional images of pancreatitis tissues in Figure S4. Patient pancreatitis tissue, representative
of n = 4. (B) Serum amylase in mice with caerulein-induced acute pancreatitis. (C) Pancreas/body
weight ratio in 1.5 month old mice with caerulein-induced acute pancreatitis. (D) Representative
images of Masson’s trichrome stain in mouse pancreas after caerulein-induced severe acute pancreatitis (scale bar = 50 µm). Quantitation of IHC detection of (E) macrophages (F4/80+ ), (F) apoptosis
(cleaved caspase 3), and (G) proliferation (BrdUrd incorporation) in pancreata of mice with caeruleininduced severe acute pancreatitis. (H) Pancreatitis damage score plotted for mice with caeruleininduced severe acute pancreatitis. (B,C,E–H) Mean ± SE is plotted; n ≥ 5 for acute and n ≥ 7 for
severe acute pancreatitis analyses; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. The number
above bar indicates fold-change induced by caerulein treatment.
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Figure 4. Loss of pancreatic PKCι expression induces oxidative stress and DNA damage.
(A) Representative images of superoxide detected by DHE staining and overlaid with DAPI staining
in pancreata of 1.5 month old Prkcif/f and Prkci∆panc mice. (B) IHC detection of p-H2A.x, p-Chk1,
and nuclear p53 in 1.5 month old Prkcif/f and Prkci∆panc mice pancreata. Bars = 100 µm. Quantitative
analysis of IHC staining is presented in the graphs below images. Mean ± SE is plotted; n ≥ 6.
** p < 0.01, *** p < 0.001.

Macroautophagy (autophagy) is a lysosome-mediated cellular process that degrades
long-lived proteins and organelles. Autophagy is activated by DNA damage and is required for cellular responses to DNA damage (reviewed in [42]). Mice with a genetic
blockade of acinar cell autophagy exhibit higher basal levels of indicators of cellular stress,
including apoptosis, immune cell infiltration, and nuclear p53 expression [9,43], similar
to the phenotype we observed in Prkci∆panc mice (Figure 1,Figure 2,Figure 4). In addition,
we observed significantly more cytoplasmic aggregates of P62 in Prkci∆panc pancreata com-
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pared to Prkcif/f pancreata (Figure 5A). Electron microscopic analysis of the pancreata of
fasted mice revealed that autophagic vesicles were readily discernible in Prkci+/+ mouse
pancreata but not in Prkci∆panc pancreata, and Prkci∆panc acinar cells contained significantly
more zymogen granules than control acinar cells (Figure 5B,C). Since both P62 and intracellular zymogen granules are degraded by autophagy [44], these observations are consistent
with a blockade of autophagy in Prkci∆panc acinar cells.

Figure 5. Pancreas-specific Prkci ablation blocks acinar cell autophagy. (A) IHC detection of P62 aggregates in pancreata of representative 1.5 month old Prkcif/f and Prkci∆panc mice (scale bar = 100 µm,
scale bar inset = 15 µm). Quantitative analysis of IHC staining is plotted below images as mean ± SE;
n = 4–7. (B) Representative images of transmission electron microcopy of pancreatic epithelial cells
of 6 week old Prkci+/+ and Prkci∆panc mice at low (left images; scale bar = 10 µm) and high magnification (right images; scale bar = 2 µm). Inset shows a single membrane autophagic vesicle (scale
bar = 333 nm). Lumen (L), nucleus (N), and autophagic vesicles (AV) are identified. (C) Quantitation
of zymogen granules/cell is plotted as mean ± SE; n = 7. Control- and rapamycin-treated Prkcf/f and
Prkci∆panc mice were analyzed by IHC for (D) P62 aggregates, (E) cleaved caspase-3, and (F) F4/80
expression in mouse pancreas. Quantitative analysis of IHC staining is plotted as mean ± SE.
n = 7–9/group; * p < 0.05, ** p < 0.01, **** p < 0.0001.

To confirm that the higher level of P62 aggregates detected in Prkci∆panc pancreas
was due to blocked autophagy, we used the mTORC1 inhibitor, rapamycin, to de-repress
mTORC1-mediated inhibition of autophagy [45]. As expected, activation of autophagy by
mTORC1 inhibition resulted in significantly less accumulated P62 aggregates in Prkci∆panc
acinar cells, without a significant effect on the already low levels of P62 aggregates in Prkcif/f
acinar cells (Figure 5D), supporting the conclusion that loss of Prkci expression blocks
acinar cell autophagy. Additionally, rapamycin treatment of Prkci∆panc mice resulted in a
significantly lower level of acinar cell apoptosis and pancreatic macrophage infiltration
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(Figure 5E,F), consistent with the well-characterized role of autophagy in protecting against
inflammation and tissue damage (reviewed in [46]).
3.4. Ablation of Pancreatic Prkci Promoted PanIN Formation but Blocked Progression to PDAC
We have previously described a required role for PKCι in the transformed growth of
pancreatic cancer cells via activation of an oncogenic RAC-MEK-ERK signaling pathway,
and we showed that high PKCι protein expression correlated with poor survival in PDAC
patients [20]. PKCι expression is elevated in KrasG12D -induced early metaplastic lesions
in the mouse pancreas and in human PanINs [22,47], and oncogenic KRAS-induced PKCι
expression in transformed pancreatic epithelial cells [48], suggesting that PKCι may play a
promotive role in the early stages of pancreatic carcinogenesis. To address this question, we
generated mice with KrasG12D -driven pancreatic cancer (KC GEMM) [8,27] and knockout of
pancreatic Prkci by crossing Prkcif/f mice with KC mice to generate LSL-KrasG12D ; Ptf1aCre/+ ;
Prkcif/f (KCI) mice. KCI mice were born at the predicted Mendelian frequency and exhibited
no significant difference in survival compared to KC mice (median survival 550 days vs.
560 days, respectively; Figure 6A; see also Figure S6A,B). At 1.5 months of age, areas
of pancreatic ADM and early PanIN lesions could be detected in both KC and KCI mice
(Figure 6B). PKCι drives a RAC-MEK-ERK signaling pathway in human PDAC cells, and
both PKCι and p-ERK are expressed at a high level in human PDAC [20]. To assess whether
PKCι also activates MEK-ERK signaling in the KC mouse model, we performed IHC for
p-ERK on KC and KCI PanIN lesions. KC PanIN lesions expressed high levels of PKCι
and p-ERK compared to KCI lesions (Figure S6C), suggesting that PKCι regulates ERK
activation in mouse PanINs. KCI PanIN lesions exhibited significantly more apoptosis,
DNA damage, and P62 aggregates compared to PanINs in KC mice (Figure 6C). Electron
microscopy showed a lack of autophagic vesicles (Figure S7A) and significantly more
zymogen granules in KCI versus KC pancreatic cells (p < 0.05; Figure S7B), indicating a
block in autophagy in KCI mouse pancreas.
We next assessed the effect of pancreatic Prkci ablation on the timing of KrasG12D induced PanIN development and progression to pancreatic cancer. As previously described [8], the pancreata of KC mice are significantly larger than those of control mice (as
measured by pancreas/body weight ratio), and this difference became more pronounced
as the mice aged (Figure S7C). In contrast, the pancreas/body weight ratio for KCI mice
remained comparable to similarly aged, control (Prkcif/f ) mice, up to 18 months of age
(Figure S7C). As described [8], the pancreata of young KC mice were comprised of mostly
normal pancreatic tissue (Figure 6D, 1.5 month old). Normal acinar cells were gradually replaced by dysplasia until only ~5% of the normal pancreatic tissue remained by
18 months of age (Figure 6D). The time course of the conversion of a normal pancreas
to dysplasia was significantly different for KCI mice, with almost 50% of the KCI mouse
normal pancreas already replaced by dysplasia by 1.5 months of age, and the remaining
normal pancreas tissue progressively lost as the mice aged (Figure 6D). To assess pancreatic
lesion progression, H&E stained pancreata from 18 month old KC and KCI mice (Figure 6E)
were evaluated for the presence of low grade dysplasia (PanIN1-2), higher grade dysplasia (PanIN3), and adenocarcinoma (see Figure S7D). Over half (54%) of the KC mice had
developed adenocarcinoma by 18 months of age (Figure 6E). Of the remaining KC mice,
31% had PanIN2 and 15% had PanIN3 as the most progressed neoplastic pancreatic lesion
(Figure 6E). In contrast, none of the KCI mice had developed adenocarcinoma by 18 months
of age, and PanINs in KCI mice were significantly less advanced. Specifically, KCI mice
exhibited predominantly low grade dysplasia with 67% PanIN1 and 33% PanIN2 lesions
at 18 months old (Figure 6E). Interestingly, the lack of progression of low grade dysplasia
(PanIN1-2) in KCI mice does not significantly prolong the survival of KCI mice compared
to KC mice (Figure 6A). While KCI mice develop only low grade dysplasia, by 18 months of
age, they have lost essentially all normal acinar cells, and therefore, their death is likely due
to pancreatic insufficiency. KC mice die at a similar age, due to pancreatic insufficiency and
tumor burden. However, the difference in disease progression between KC and KCI mice
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strongly supports a promotive role for PKCι in oncogenic KrasG12D -driven progression of
preneoplastic PanIN lesions to malignant adenocarcinoma.

Figure 6. Pancreas-specific Prkci knockout increases early KrasG12D -mediated PanIN formation, but
blocks progression to adenocarcinoma and alters immune cell infiltration. (A) Kaplan-Meier analysis
of overall survival of KC and KCI mice (n = 51, 50, respectively). (B) Representative images of Alcian
blue-stained pancreas from 1.5 month old KC and KCI mice (scale bar = 100 µm). (C) Representative
images (top) and quantitative analysis of IHC detection (bottom) of cleaved caspase-3, p-H2A.x, and
P62 aggregates in PanIN lesions of 1.5 month old KC and KCI mice, (scale bar = 50 µm). Results
plotted as mean ± SE; n = 4–5; * p < 0.05. (D) Quantitation of area of abnormal tissue (ADM,
dysplasia, and PDAC) in KC and KCI mouse pancreas is plotted; n ≥ 6, ** p < 0.01 compared to
KC. (E) Representative images of H&E stained pancreas from 18 month old KC and KCI mice are
shown (left; scale bar = 200 µM). Neoplastic progression of 18 month old KC and KCI mice is plotted;
(right; n = 13, 9; see also Figure S7D). Quantitative analysis of IHC detection of (F) T cells (CD3+ ),
(G) neutrophils (Ly6.B+ ), (H) macrophages (F4/80+ ), (I) M1 polarized macrophages (iNOS+ ), and
(J) M2 polarized macrophages (ARG1+ ) in pancreatic lesions of 18 month old KC and KCI mice. IHC
quantitation is plotted as mean ± SE; n = 6–15. * p < 0.05.
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The relationship between the immune system and pancreatic cancer development
is complex. Pancreatic inflammation, including immune cell infiltration associated with
pancreatitis, can promote the initiation of pancreatic cancer lesion formation [39,49], while
subsequent growth and progression of KrasG12D -driven pancreatic cancer are supported by
the recruitment of immune cells that generate a permissive, immunosuppressive tumor
microenvironment [50–52]. Therefore, we assessed the effect of loss of Prkci expression
on infiltrating immune cells in KrasG12D -driven dysplastic pancreatic lesions. The relative
levels of immune cells in early pancreatic lesions in 1.5 month old KC and KCI mice were
similar to the differences observed in the pancreata of a 1.5 month old Prkcif/f and Prkci∆panc
mouse, with significantly more macrophage and T cells associated with KCI lesions compared to KC lesions (Figure S8A–C). At 18 months of age, immune cell distribution had
changed such that similar levels of T cells (Figure 6F) and neutrophils (Figure 6G) were
observed in the pancreas of KC and KCI mice. Significantly fewer macrophages, the major
form of immune cell in developing murine KrasG12D -driven PDAC [53], were detected in
the pancreas of 18 month old KCI mice compared to KC mice (Figure 6H). While there
was no difference in the abundance of cells expressing iNOS, a marker of M1 classically
activated (pro-inflammatory) macrophages [54], significantly fewer cells expressing ARG1,
a marker of M2 alternatively activated (anti-inflammatory) macrophages [54] were observed in KCI pancreas (Figure 6I,J), suggesting that pancreatic Prkci expression plays a role
in the establishment of the immunosuppressive tumor microenvironment permissive for
pancreatic tumor progression [50,55–57].
3.5. PRKCI Expression and Signaling Activity Predicted Poor Survival and were Positively
Associated with Autophagy Risk Signature in Human PDAC Tumors
Both PRKCI mRNA and protein expression levels have been shown to predict poor
PDAC patient survival [19,20]. To investigate the clinical relevance of PRKCI signaling in
human pancreatic cancer, we assessed the association of PRKCI expression, PRKCI copy
number, and signaling activity with PDAC tumor characteristics and patient outcomes.
Primary PDAC tumors within the TCGA pancreatic adenocarcinoma dataset were segregated by PRKCI mRNA expression level into two groups optimized for survival outcomes.
The high PRKCI mRNA/poor PDAC patient survival group had a median survival time of
8.7 months while the low PRKCI mRNA/better PDAC patient survival group had a median
survival time of 19.8 months (p < 0.0001) (Figure S8A). We have shown that frequent PRKCI
CNGs at chromosomal region 3q26 occur in many types of human cancers including PDAC,
and CNGs serve as a driver of PRKCI expression in PDAC [58,59]. As predicted by our
previous studies, PDAC tumors harboring PRKCI CNGs were significantly enriched in
the high PRKCI group (Figure 7A) and PDAC patients with PRKCI CNGs experienced
significantly worse overall survival than PDAC patients without PRKCI CNGs (median
survival time 9.6 months vs 19.9 months, respectively; Figure 7B), indicating that PRKCI
CNG-driven PRKCI expression is clinically significant and that PRKCI expression and
PRKCI CNG may be useful as biomarkers of poor patient outcome.
We recently reported that 3q26 CNGs in PDAC drive coordinate overexpression of
PRKCI and ECT2, a PRKCI signaling partner also located on 3q26 [59]. Functionally, PKCιECT2 signaling drives two signaling pathways required for the transformed growth of
lung cancer cells, RAC-MEK-ERK proliferative signaling, and rDNA transcription and
expression of ribosomal RNA processing genes [60–63]. PKCι-RAC-MEK-ERK signaling
also plays a critical role in the transformed growth of PDAC cells [20] and in this report, we
show that loss of Prkci expression is associated with lower levels of p-ERK in mouse PanINs
(Figure S6C), consistent with the association of PKCι and p-ERK expression in PDAC
patient tissues [20]. Therefore, we investigated the clinical relevance of the association of
PRKCI expression with RAC-MEK-ERK signaling in PDAC. Differential gene expression
analysis of the 25% of TCGA PDAC tumors with the highest PRKCI expression compared
to the 25% of PDAC with the lowest level of PRKCI expression was performed as described
in Methods. IPA analysis of differentially expressed genes revealed that high PRKCI
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expression was positively and significantly associated with active RAC and ERK/MAPK
signaling pathways in human PDAC (Figure 7C), strongly supporting the clinical relevance
of PKCι-RAC-MEK-ERK signaling in PDAC.

Figure 7. Characterization of PRKCI in human PDAC. (A) Distribution of tumors without PRKCI
CNG (GISTIC score −1, 0) and with PRKCI CNG (GISTIC score +1, +2) in low PRKCI and high PRKCI
groups defined in Figure S9A. Fisher exact analysis was used to assess the significance of differences
between groups. (B) Kaplan-Meier analysis of overall survival of PDAC patients surviving >30 days
after surgery with PRKCI CNG (n = 25) and no PRKCI CNG (n = 113) is plotted. (C) Gene expression
analysis of the TCGA PDAC dataset identified genes with a significant difference in expression
between the 25% PDAC tumors with the highest PRKCI expression (n = 36) and the 25% PDAC
tumors with the lowest PRKCI expression (n = 36). Ingenuity pathway analysis of differentially
expressed genes revealed signaling pathways that are significantly altered between the groups. Bars
represent the (−log) p-values of the significance of the pathway and the number to the right indicates
the z score. Black bars indicated pathways with a positive z score, red bars indicate pathways with
negative z scores. (D) Scatter plot showing the relationship between log PRKCI mRNA expression and
the PRKCI-ECT2 pathway score in all TCGA PDAC. (E) Scatter plot showing the relationship between
log PRKCI mRNA expression and autophagy risk score in all TCGA PDAC tumors. (F) Scatter plot
showing the relationship between PRKCI-ECT2 pathway score and autophagy risk score in all TCGA
PDAC. Spearman’s correlation coefficient (R) and significance (p-value) are indicated in panels (D–F).
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Next, we assessed the clinical relevance of the PKCι-ECT2 driven rDNA transcription
pathway in PDAC. We previously reported that a PRKCI-ECT2 signaling activity score,
calculated from a lung squamous cell carcinoma PKCι-ECT2-signaling-dependent gene
signature, predicted poor survival of patients with numerous cancer types, including
PDAC [59]. As in lung squamous cell carcinoma, expression of genes critical to ribosome biogenesis strongly correlate with both PRKCI and ECT2 mRNA expression in the
PDAC dataset (100/286 ribosome biogenesis genes p < 0.01 for both PRKCI and ECT2; see
Table S2), suggesting PKCι-ECT2-signaling drives ribosome biogenesis in PDAC. Therefore,
we generated a PDAC-specific PRKCI-ECT2 ribosome biogenesis signature consisting of
the top 10% of ribosome processing genes whose expression positively and significantly
correlated with both PRKCI and ECT2 expression in PDAC tumors (Figure S9B). We used
this gene signature to calculate a PRKCI-ECT2 pathway activity score for all PDAC tumors in this dataset. The PRKCI-ECT2 pathway activity score was significantly higher in
the high PRKCI/poor survival group compared to the low PRKCI/better survival group
(Figure S9C), and strongly correlated with PRKCI expression in the entire PDAC dataset
(Figure 7D). Likewise, the PRKCI-ECT2 pathway score was significantly higher in PDAC
with PRKCI CNGs (Figure S9D).
We next investigated the association of PRKCI expression and signaling with autophagy in PDAC patient tumors. IPA analysis revealed no enrichment of the canonical
autophagy signaling pathway in high PRKCI tumors compared to low PRKCI tumors (-log
p-value = 0, z score not calculated). However, a PDAC-specific, autophagy-related gene
expression signature has been described which predicts poor PDAC patient survival [35].
This PDAC-specific autophagy risk score was significantly higher in high PRKCI/poor
survival PDAC tumors (Figure S8E) and strongly correlated with PRKCI expression over
the entire PDAC dataset (Figure 7E). Likewise, the autophagy risk score was significantly
higher in PDAC with PRKCI CNGs (Figure S8F). Finally, the autophagy risk score was also
strongly correlated with the PRKCI-ECT2 activity score (Figure 7F). Taken together with our
preclinical data, we demonstrate for the first time a strong, clinically relevant association
between PKCι signaling and autophagy-associated poor survival in PDAC.
High autophagy risk scores were associated with increased macrophage infiltration,
but decreased levels of protective immune cells [35], in keeping with the recently described
role for autophagy in promoting an immune-suppressive PDAC tumor microenvironment [57,64]. Interestingly, IPA analysis revealed that compared to low PRKCI tumors, high
PRKCI tumors exhibit a significant reduction in several immune cell signaling pathways
(Figure 7C). These include the OX40 and iCOS-iCOSL costimulatory signaling pathways
which promote T cell survival and activation of T helper cells [65,66]. The Th 1 and
“crosstalk between dendritic cells and natural killer (NK) cells” anti-tumor immune signaling pathways [67,68] were also significantly lower in High PRKCI tumors (Figure 7C). This
strong negative relationship between anti-tumor signaling pathways and PRKCI expression
suggests high PRKCI in PDAC promotes immune suppression.
4. Discussion
PRKCI was first characterized as an oncogene in lung and ovarian cancers; its role in
other cancer types continues to be described [13,16,18,20,24,62,69–71]. We and others have
shown that PKCι expression is significantly elevated in oncogenic KrasG12D -transformed,
metaplastic pancreatic acinar cells, suggesting that PKCι plays a significant role in the
initiation of pancreatic cancer [22,47]. In this study, we investigated the role of PKCι
in pancreas homeostasis, susceptibility to pancreatitis, and initiation and progression of
KrasG12D -driven pancreatic cancer. We report that ablation of PKCι expression in the mouse
pancreas altered the pancreatic immune cell population, reduced the severity of caeruleininduced pancreatitis, and blocked KrasG12D -driven progression of PanINs to pancreatic
cancer, revealing for the first time a role for PKCι in the promotion of PDAC in mice.
Knockout of PKCι expression in the mouse pancreas promoted apoptosis, immune
cell infiltration, and increased markers of cellular stress. Although Prkci∆panc mice exhibited
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a higher level of pancreatic immune cell infiltration, these mice were less susceptible to
caerulein-induced pancreatitis. Pancreatitis is a progressive systemic disease with no
effective targeted therapy, and severe acute pancreatitis is a risk factor for PDAC [49,72].
The relationship between pancreatitis and autophagy is complex; acute pancreatitis is
shown to activate autophagy but also inhibit autophagic flux (reviewed in [73]). Enhancing
autophagy activity improved L-arginine-induced pancreatitis [74], while inhibition of
autophagy in caerulein-stimulated mouse acinar cells blocked trypsinogen activation [75].
Knockout of the essential autophagy gene, Atg5, in the mouse pancreas blocked acinar
cell autophagy and reduced caerulein-induced pancreatitis, implicating autophagy in
pancreatitis-induced tissue damage [44]. Likewise, our results show that loss of PKCι
expression blocked acinar cell autophagy and reduced the severity of caerulein-induced
pancreatitis. However, while loss of pancreatic Prkci expression induces some of the
basal phenotypes associated with the genetic blockade of cellular autophagy, including
increased apoptosis, cellular stress, and immune cell infiltration, pancreatic Prkci ablation
did not reduce overall mouse survival or promote the widespread pancreatic degeneration
observed in Atg5 knockout mice, suggesting PKCι plays a role distinct from Atg5 in the
regulation of autophagy and cellular homeostasis [9,43,76].
Using a mouse acinar cell explant model [77,78], we have shown that genetic or
pharmacological inhibition of PKCι significantly suppressed KrasG12D -induced ADM in
ex vivo culture [22]. This suggested that PKCι is required for KrasG12D -driven initiation
of pancreatic cancer, similar to the established role for PKCι in KrasG12D -initiated mouse
lung cancer [16,79]. The unexpected acceleration of KrasG12D -driven ADM and PanIN
formation upon pancreatic Prkci ablation in vivo supports a non-cell autonomous role for
PKCι in promoting pancreatic tumor initiation. In vivo, pancreatic ablation of Prkci blocks
autophagy, and like genetic inhibition of autophagy (Atg5 knockout), Prkci ablation promotes increased DNA damage and recruitment of immune cells [9,76]. Interestingly, Zhu
et al. recently identified autophagy as an essential, non-cell autonomous metabolic process
required for KrasG12D /Trp53R172H mutant mouse pancreatic cancer cell tumor growth [57].
Autophagy was uniquely required for in vivo, but not in vitro pancreatic cancer cell growth,
and this requirement was specific for pancreatic, but not lung, tumor growth. Zhu et al.
further showed that the dependency on autophagy for tumor cell growth only existed
in the presence of an intact immune system, suggesting that a major role of autophagy
in pancreatic cancer cells is to promote immune evasion, consistent with reports that an
autophagy blockade activates the innate immune response in pancreatic tumors [57,64].
In line with these reports, we show that ablation of pancreatic Prkci expression in the
KC KrasG12D -driven PDAC GEMM altered immune cell infiltration of pancreatic lesions.
At later time points, KCI pancreatic lesions recruited significantly fewer macrophages, a
cell type associated with poor PDAC patient survival [80], with a specific reduction in
the levels of ARG1+ macrophages, an immunosuppressive subset of tumor-associated
macrophages [81]. Therefore, the lack of progression of low grade dysplasia in KCI mice
is likely due to disruption of autophagy and immune suppression that are required for
progression of KrasG12D -driven pancreatic lesions to PDAC [50,82,83]. We further demonstrated that high PRKCI expression in PDAC is associated with reduced activation of several
immune signaling pathways implicated in the improved survival of PDAC cancer patients,
including OX40, iCOS, and Th1 signaling [84–87].
IPA analysis revealed that high PRKCI expression in PDAC was not associated with
increased canonical autophagy signaling, suggesting PRKCI does not regulate autophagy at
the level of gene expression. An extensive proteomic analysis of the human autophagy system characterized an autophagy interaction network under basal autophagy conditions [88].
PKCι was identified as a protein that interacts with multiple ATG8 family members, which
are known to play a critical role in autophagosome assembly, maturation and lysosome
maturation, and cargo recruitment [88]. PKCι also binds the autophagy cargo adaptor
P62 via PB1-PB1 domain-mediated interactions [89]. Therefore, protein-protein interactions and signaling complex formation may be important for PKCι-mediated regulation
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of autophagy in the pancreas. Future studies will address the mechanism by which Prkci
regulates pancreatic cell autophagy.
Autophagy is currently being investigated as a novel target for chemotherapy. Preclinical studies in pancreatic cancer GEMMs have demonstrated a therapeutic effect of
the autophagy inhibitor, hydroxychloroquine [76,90]; however, hydroxychloroquine as a
mono-therapy did not elicit a therapeutic effect in a clinical trial of metastatic pancreatic
cancer patients [91]. Recent studies assessing hydroxychloroquine in combination with
chemotherapy reveal positive pathologic tumor response in the context of resectable tumors [92–94], suggesting more effective inhibitors of autophagy, or combination therapies
incorporating autophagy inhibitors, may be clinically useful. A well-characterized inhibitor
of PKCι oncogenic signaling, Auranofin, is clinically available and has been previously
shown to inhibit transformed growth and growth of human cancer cells as xenograft tumors, including PDAC cells [18,95–97]. Since high PRKCI expression is associated not only
with elevated ERK signaling and high autophagy risk score, but also with lower activities
of anti-tumors immune signaling pathways, targeting PKCι may not only inhibit oncogenic
signaling, but also reactivate immune protective signaling, such as the T cell activation
and survival promoted by the co-stimulatory iCOS and OX40 signaling pathways, and the
activation of tumor-targeting NK cells [68]. Interestingly, a recent preclinical PDAC study
revealed that reactivation of the OX40 pathway in combination with an immune checkpoint
inhibitor induced tumor rejection and immune memory in a mouse model [86]. Another
recent study demonstrated that an agonist of CD40 (another co-stimulatory activator of T
cells), in combination with inhibitors of MEK and autophagy, activated anti-tumor immunity and inhibited PDAC growth in a mouse model [84] indicating the potential relevance
of therapeutically targeting PKCι. The results of this study suggest that further investigation of PKCι-targeted therapy for the treatment of PDAC, perhaps in combination with
autophagy inhibitors such as chloroquine, or immune checkpoint inhibitors, is warranted.
5. Conclusions
We previously showed that inhibition of PKCι expression or activity blocks human
PDAC cell growth in vitro and in vivo [20,95]. In this report, we demonstrate a previously
uncharacterized role for PKCι in the regulation of pancreatic cell autophagy, such that
knockout of pancreatic Prkci protected mice from KrasG12D -mediated pancreatic cancer
development. PRKCI expression and signaling activity exhibit strong positive correlations
with poor overall patient survival and an independent autophagy-driven, signature of
poor PDAC patient survival, while PRKCI expression negatively correlates with multiple
anti-tumor immunity pathways, providing clinical relevance to our observation that PKCι
plays a promotive role in murine PDAC development.
6. Patents
A provisional patent related to this research has been filed (MSB, APF, NRM; Methods
and Materials for treating pancreatic cancer, US Patent Application #20110190390).
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/cancers14030796/s1. Figure S1: Pancreas-specific Prkci ablation
does not have sex-specific effects on overall survival. Figure S2: Full blots of data presented in
Figure 1B. Figure S3: Pancreas-specific Prkci ablation does not have sex-specific effects on body weight.
Figure S4: Larger images of IHC detection of PKCι expression in pancreatitis tissues. Figure S5:
Pancreas-specific Prkci ablation does not induce histological alterations or pancreatitis in aged mice.
Figure S6: Pancreas-specific Prkci ablation does not have sex-specific effects on survival of mice with
KrasG12D -driven pancreatic lesion formation. Figure S7: Pancreas-specific Prkci ablation leads to
decreased autophagic vesicles and increased zymogen granules in KrasG12D -expressing pancreas.
Figure S8: Immune cell infiltration of PanIN lesions. Figure S9: Characterizing the relationship
between PRKCI expression, PRKCI-ECT2 signaling and au-tophagy risk score. Table S1: List of
antibodies used. Table S2: 286 genes identified as significantly required for pre-rRNA processing.
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